AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 36442467
Drug: Late feeding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late feeding group (4 days of trophic feeding at 20-24 mL/kg/day)
Trial: 33526496
Drug: Describing side
RxNorm normalized name: cured fat, pork side bacon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Describing side effects as a sign treatment is working
Trial: 35315017
Drug: Calcium channel
RxNorm normalized name: Calcium channel blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium channel blockers (nifedipine, nicardipine)
Trial: 34476447
Drug: Continuous oral
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous oral health education after treatments
Trial: 34476447
Drug: Clinical education
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical education at the time of treatments
Trial: 33312712
Drug: Extracorporeal shock
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal shock wave therapy (ESWT), low-energy intervention group, treated once a week for 10 weeks.
Trial: 32690105
Drug: NEON Intervention
RxNorm normalized name: neon
DrugBank: Neon (DB11589)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NEON Intervention (treatment as usual plus immediate access to the NEON Intervention for 1 year)
Trial: 32690105
Drug: Cost-effectiveness analysis
RxNorm normalized name: Chemicals and reagents for analysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cost-effectiveness analysis using EQ‐5D‐5 L and Client Service Receipt Inventory data
Trial: 32690105
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual plus access to the NEON Intervention after 1 year
Trial: 35985418
Drug: 12-month home-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-month home-based physical exercise (supervised by physiotherapist, 60 minutes, twice a week)
Trial: 34938893
Drug: Oral magnesium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral magnesium oxide (MgOx)
Trial: 34938893
Drug: Oral magnesium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral magnesium citrate (MgCit)
Trial: 35181385
Drug: Open-label placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label placebo (OLP) nasal spray
Trial: 34314511
Drug: PCV13 (13-valent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCV13 (13-valent pneumococcal conjugate vaccines)
Trial: 34314511
Drug: Diphtheria toxoid
RxNorm normalized name: diphtheria toxoid
DrugBank: Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (DB10584)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphtheria toxoid and tetanus toxoid vaccine
Trial: 33499887
Drug: Prednisone 40
RxNorm normalized name: prednisone 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone 40 mg days 1 to 4, then 20 mg days 5 to 8
Trial: 32891139
Drug: Weekly vitamin
RxNorm normalized name: Ezy Dose Weekly Vitamin Planner 2XL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly vitamin D2 50,000 IU
Trial: 32891139
Drug: Weekly vitamin
RxNorm normalized name: Ezy Dose Weekly Vitamin Planner 2XL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly vitamin D2 2500 IU
Trial: 32816890
Drug: Axitinib (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Axitinib (5 mg twice daily) and Pembrolizumab (2 mg/kg every 3 weeks)
Trial: 32569429
Drug: Topical 0.1%
RxNorm normalized name: adapalene topical 0.1% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.1% capsaicin cream
Trial: 36394475
Drug: Regular low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Regular low-dose sustained-release morphine (0/8/16/24 mg every 24 hours)
Trial: 34187862
Drug: Home medication
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home medication
Trial: 34187862
Drug: Nonhome medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonhome medication
Trial: 37099968
Drug: ADT +
RxNorm normalized name: Antidepressant+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADT + brexpiprazole 2-3 mg/day
Trial: 35658908
Drug: Deep Learning
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep Learning Image Reconstruction (DLIR) - Low intensity (L)
Trial: 32885419
Drug: Okara soup
RxNorm normalized name: MALT SOUP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Okara soup (4.1 g fiber/meal)
Trial: 32885419
Drug: Placebo (soymilk,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (soymilk, 0.1 g fiber/meal)
Trial: 35610666
Drug: GeneXpert® point‐of‐care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GeneXpert® point‐of‐care diagnostic testing for Neisseria gonorrhoeae, Chlamydia trachomatis, and Trichomonas vaginalis, with same‐day treatment for detected infection(s). Arm 1 will additionally receive a test‐of‐cure 3 weeks post‐treatment, while Arm 2 will receive a repeat test at 30‐34 weeks' gestation.
Trial: 36099496
Drug: Rectal diclofenac
RxNorm normalized name: diclofenac Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal diclofenac (NSAID) 50 mg
Trial: 36099496
Drug: Both pancreatic
RxNorm normalized name: Pancreatin
DrugBank: Pancrelipase (DB00085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both pancreatic stent placement and rectal NSAIDs (PS + NSAID)
Trial: 33629812
Drug: 24 mg
RxNorm normalized name: uracil 224 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 mg day-1 xanthohumol for eight weeks
Trial: 32862830
Drug: 1 dose
RxNorm normalized name: Ribose 3 GM/1 DOSE Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 dose of RBX2660 via enema
Trial: 32862830
Drug: 2 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of RBX2660 via enema
Trial: 32875946
Drug: Potassium hydroxide
RxNorm normalized name: Potassium Hydroxide
DrugBank: Potassium hydroxide (DB11153)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium hydroxide 5% solution (KOH)
Trial: 32875946
Drug: 5-fluorouracil cream
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluorouracil cream (5-FU)
Trial: 32054509
Drug: 4-week oral
RxNorm normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-week oral Phe administration
Trial: 32054509
Drug: 4-week placebo
RxNorm normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-week placebo administration
Trial: 36235623
Drug: Alpha-Glycerylphosphorylcholine (A-GPC)
RxNorm normalized name: glycerylphosphorylcholine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-Glycerylphosphorylcholine (A-GPC) 1000 mg
Trial: 32530769
Drug: Cisplatin plus
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin plus FU (60 mg/m2 on day 1 and 1,000 mg/m2 on days 1-4 every 21 days for 24 weeks)
Trial: 32530769
Drug: Carboplatin plus
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin plus paclitaxel (AUC 5 on day 1 and 80 mg/m2 on days 1, 8, and 15 every 28 days for 24 weeks)
Trial: 35459000
Drug: Vibrotactile sensory
RxNorm normalized name: aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Vibrotactile sensory augmentation (SA)
Trial: 34529887
Drug: Multimodal preemptive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal preemptive analgesia (flurbiprofen axetil and oxycodone before skin incision combined with bilateral transverse abdominis plane block)
Trial: 32558314
Drug: Antimicrobial peptide
RxNorm normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial peptide KSL‐W formulated as an antiplaque chewing gum (APCG), 30 mg, administered three times per day for four days
Trial: 33787834
Drug: Revacept 80
RxNorm normalized name: Revacept
DrugBank: PR-15 (DB06037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Revacept 80 mg
Trial: 35526272
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose adalimumab regimen
Trial: 33004464
Drug: Empagliflozin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin (10 and 25 mg)
Trial: 36435427
Drug: AI-optimized weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AI-optimized weekly interventions (combination of expert-led group, expert-led call, paraprofessional-led call, and automated message)
Trial: 36435427
Drug: Gold standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gold standard condition (12 months of weekly BWL groups)
Trial: 32811637
Drug: Fixed-dose of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose of nine sessions of MET/CBT
Trial: 32811637
Drug: PRN condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRN condition with smaller initial dose of treatment
Trial: 32811637
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (MET/CBT and PRN)
Trial: 34714961
Drug: Point-by-point technique
RxNorm normalized name: APPLICATOR POINTED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Point-by-point technique injection
Trial: 34628065
Drug: Dupilumab 300
RxNorm normalized name: dupilumab 300 MG in 2 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab 300 mg subcutaneously every 2 weeks for 24 weeks
Trial: 34805810
Drug: PB-201 50+50
RxNorm normalized name: PB-722
DrugBank: PB-722 (DB18447)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PB-201 50+50 mg
Trial: 34805810
Drug: PB-201 100+50
RxNorm normalized name: PB-722
DrugBank: PB-722 (DB18447)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PB-201 100+50 mg
Trial: 34805810
Drug: PB-201 100+100
RxNorm normalized name: PB-722
DrugBank: PB-722 (DB18447)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PB-201 100+100 mg
Trial: 33013035
Drug: Erector spinae
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erector spinae plane (ESP) block with 0.2% ropivacaine (0.2 ml/kg on either side)
Trial: 33013035
Drug: Transversus abdominis
RxNorm normalized name: PAD,ABDOMINAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transversus abdominis plane (TAP) block with 0.2% ropivacaine (0.2 ml/kg on either side)
Trial: 32516497
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of home-use microneedle device and 5% minoxidil solution
Trial: 32516497
Drug: 5% minoxidil
RxNorm normalized name: MINOXIDIL 5 g in 100 mL TOPICAL LIQUID [ASDTOTIO 5% minoxidil]
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5% minoxidil topical solution only
Trial: 34861168
Drug: ianalumab 5
RxNorm normalized name: Ianalumab
DrugBank: Ianalumab (DB16666)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ianalumab 5 mg
Trial: 34861168
Drug: ianalumab 50
RxNorm normalized name: Ianalumab
DrugBank: Ianalumab (DB16666)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ianalumab 50 mg
Trial: 34861168
Drug: ianalumab 300
RxNorm normalized name: Ianalumab
DrugBank: Ianalumab (DB16666)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ianalumab 300 mg
Trial: 35623816
Drug: Stevia (15.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stevia (15.3 mg)
Trial: 35623816
Drug: d-tagatose (5000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-tagatose (5000 mg)
Trial: 35623816
Drug: Control (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (60 mL water)
Trial: 33610836
Drug: ranibizumab (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ranibizumab (0.5 mg/50 μl)
Trial: 33610836
Drug: aflibercept (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aflibercept (2.0 mg/50 μl)
Trial: 33610836
Drug: bevacizumab (1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bevacizumab (1.25 mg/50 μl)
Trial: 33677048
Drug: Involved-field irradiation
RxNorm normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Involved-field irradiation with definitive chemoradiation therapy (61.2 Gy in 34 fractions using intensity modulated radiation therapy)
Trial: 33677048
Drug: Involved-field irradiation
RxNorm normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Involved-field irradiation with definitive chemoradiation therapy
Trial: 36030811
Drug: Telemedicine group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telemedicine group (asynchronous online consultation, 200 mg mifepristone and 800 μg misoprostol at home)
Trial: 36030811
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care group (in-person consultation, 200 mg mifepristone in clinic and 800 μg misoprostol at home)
Trial: 36045818
Drug: 400 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 μg of rectal misoprostol
Trial: 35666231
Drug: SDX/d-MPH 26.1/5.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SDX/d-MPH 26.1/5.2 mg (Treatment A)
Trial: 35666231
Drug: SDX/d-MPH 39.2/7.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SDX/d-MPH 39.2/7.8 mg (Treatment B)
Trial: 35666231
Drug: SDX/d-MPH 52.3/10.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SDX/d-MPH 52.3/10.4 mg (Treatment C)
Trial: 35666231
Drug: SDX/d-MPH 52.3/10.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SDX/d-MPH 52.3/10.4 mg (multiple dosing)
Trial: 33767064
Drug: SGLT2 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SGLT2 inhibitors (specific types not mentioned)
Trial: 33767064
Drug: SGLT2 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SGLT2 inhibitors (empagliflozin)
Trial: 35807922
Drug: Graded Protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Graded Protein (GP) diet (0.8 g/kg/d at week 1 to 2.2 g/kg/d at week 10 with whey protein supplement)
Trial: 35807922
Drug: Constant Protein
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constant Protein (CP) diet (0.8-1.0 g/kg/d with no protein supplement)
Trial: 33715655
Drug: Spray-on 80%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spray-on 80% Cu-20% Ni (spray-on)
Trial: 33780463
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment group (n=253)
Trial: 35475948
Drug: Diesel exhaust
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diesel exhaust exposure (particle mass concentrations around 300 µg/m3)
Trial: 35301888
Drug: rosuvastatin monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosuvastatin monotherapy
Trial: 35301888
Drug: rosuvastatin/ezetimibe combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosuvastatin/ezetimibe combination therapy
Trial: 34268884
Drug: Oral metformin
RxNorm normalized name: metformin Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral metformin (1 g) with codeine (25 mg)
Trial: 34268884
Drug: Intravenous metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous metformin (0.5 g) with codeine (25 mg)
Trial: 34268884
Drug: Oral metformin
RxNorm normalized name: metformin Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral metformin (1 g) without codeine
Trial: 34268884
Drug: Intravenous metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous metformin (0.5 g) without codeine
Trial: 34743319
Drug: Escitalopram (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram (10 mg daily for 7 days, then 20 mg daily for 7 days)
Trial: 34743319
Drug: Placebo (14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (14 days before psilocybin administration)
Trial: 38326432
Drug: Psilocybin (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psilocybin (25 mg)
Trial: 34423676
Drug: Brigatinib 180
RxNorm normalized name: brigatinib 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brigatinib 180 mg once daily (with a 7-day lead-in at 90 mg once daily)
Trial: 32039739
Drug: Emotion regulation
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Emotion regulation training in addition to care as usual (multidisciplinary obesity treatment)
Trial: 32039739
Drug: Care as
RxNorm normalized name: TopCare Aspirin 325mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Care as usual (multidisciplinary obesity treatment)
Trial: 32583907
Drug: Minesapride 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minesapride 10 mg/d
Trial: 32583907
Drug: Minesapride 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minesapride 20 mg/d
Trial: 32583907
Drug: Minesapride 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minesapride 40 mg/d
Trial: 34455152
Drug: Bilateral continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral continuous T8 ESP blocks with a programmed intermittent bolus regimen of 10 mL 0.2% ropivacaine every 3 h for 48 h (n=30)
Trial: 34455152
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine (ITM) 400 μg (n=30)
Trial: 32037195
Drug: Demcizumab (DLL4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Demcizumab (DLL4 targeted IgG2 humanized monoclonal antibody) combined with paclitaxel (2.5 mg/kg and 5 mg/kg doses); administered on days 1 and 15 for 3 cycles, followed by paclitaxel until unacceptable toxicity or disease progression.
Trial: 34819150
Drug: Unilateral quadratus
RxNorm normalized name: Pisum quadratum whole
DrugBank: Pisum sativum whole (DB15545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unilateral quadratus lumborum block (QLB) with 0.375% bupivacaine 0.5 mL/kg (QLB group)
Trial: 32191267
Drug: Ranibizumab or
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab or Bevacizumab (protocol-guided treatment)
Trial: 32191267
Drug: Switched drug
RxNorm normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switched drug regimen
Trial: 33943011
Drug: S +
RxNorm normalized name: K-Y Yours + Mine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S + POCT (surgery plus postoperative chemotherapy)
Trial: 33744963
Drug: Daily co-trimoxazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily co-trimoxazole
Trial: 37656441
Drug: Corticosteroid monotherapy
RxNorm normalized name: abiraterone and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid monotherapy
Trial: 34181360
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg VLX-ER
Trial: 34181360
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg VLX-ER
Trial: 36263928
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine 300 U/ml (Gla-300)
Trial: 35840157
Drug: Etanercept (ETN)
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept (ETN) 50 mg once weekly
Trial: 33549193
Drug: Ustekinumab 45
RxNorm normalized name: USTEKINUMAB 45MG/0.5ML INJ 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ustekinumab 45 mg or 90 mg every 12 weeks
Trial: 34157675
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of exercise snacking and tai chi snacking
Trial: 32700217
Drug: TIME program
RxNorm normalized name: Return 10 TIME LOCK PROGRAM KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TIME program (Telehealth-supported, Integrated care with CHWs, and MEdication-access)
Trial: 34187117
Drug: EGCG (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGCG (2 tablets, 300 mg)
Trial: 34927342
Drug: Subcision combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcision combined with poly-l-lactic acid (PLLA) threads
Trial: 32919816
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 supplementation (100,000 IU monthly)
Trial: 35514231
Drug: Edelweiss extract
RxNorm normalized name: edelweiss root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edelweiss extract formulation
Trial: 33478428
Drug: Weekly rifapentine
RxNorm normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly rifapentine and isoniazid regimen (self-administered for 12 weeks)
Trial: 33478428
Drug: Daily rifampicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily rifampicin and isoniazid regimen (self-administered for 12 weeks)
Trial: 33478428
Drug: Both arms
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both arms (weekly rifapentine/isoniazid and daily rifampicin/isoniazid)
Trial: 33552685
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of pembrolizumab with platinum-based chemotherapy (PCT)